Compare Matson Inc (MATX) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Matson Inc vs Mesoblast Limited — how do they compare? Matson Inc trades at $229 (market cap $6.81B), while Mesoblast Limited trades at $13.8 (market cap $1.75B). The key difference: Matson Inc is far larger — about 3.9× Mesoblast Limited's market cap, and Matson Inc pays a 0.67% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Matson Inc for 23 Days and Mesoblast Limited for 14 Days on average.
| MATX | MESO | |
|---|---|---|
Market Cap | $6.81B | $1.75B |
Volume | 255,080 | 239,027 |
Sector | Industrials | Health |
52-Week High | $238.60 | $20.96 |
52-Week Low | $88.05 | $13.19 |
Typical Hold Time | 23 Days | 14 Days |
Enterprise Value | $7.41B | $1.83B |
Dividend Yield | 0.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Matson (MATX) trades at $222.92, down 0.83% today, with neutral technical signals and strong fundamental performance. The stock shows robust earnings momentum with three consecutive quarterly beats, including Q2 2026 EPS of $4.27 versus $3.79 expected. Revenue growth continues with 2026 projections reaching $3.5 billion, supported by a 13.4% net income margin. Recent news highlights institutional buying interest and positive analyst sentiment.
MATX presents a compelling investment case with solid profitability metrics and analyst support, though near-term technical resistance at $224 may limit upside. The company's raised full-year outlook and consistent dividend payments provide stability, while exposure to freight market volatility remains a key risk factor for shareholders.
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Matson Inc
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
